TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Immunoglobulin G
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of biomarkers in FFPE tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of surveys completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Global Impression of Change (PGIC) rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in correct answer rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of migraine headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Driving Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Cancer Screening Uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean System Usability Score (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Satisfaction With Personalized Trial Components
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Usability and Engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OAB knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Modified Fatigue Impact Score (MFIS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sensitivity of Biozek Covid-19 Antigen Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Biozek Covid-19 Antigen Rapid Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration - time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Severe Maternal Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants experiencing an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with increased physical activity enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: System Usability Scale score (0 to 100) for Daily Goal Sessions & Fitbit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in baseline systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fasting high-density lipoprotein (HDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ascites- and pleural effusion-associated symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implantation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of major adverse events, infections and device deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea (acute toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in urine protein-to-creatinine ratio (uPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Motor fluctuations changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Dyskinesia changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Changes in the Autism Behavior Checklist (ABC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Ethylglucuronide (EtG) Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Recent Drinking With Timeline Followback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the number of acute heart failure episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiofic changes of diastolic left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of men who discontinue daily oral PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of men who initiate on-demand oral PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of men who initiate long-acting injectable PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of STI diagnoses from baseline at 12 and 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: D02 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone quality identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Vessel density changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relapse within 6-8 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in titer of IgG antibodies to N-protein of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of symptomatic COVID-19 with laboratory-confirmed infection within 6 months after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: 26-week change in albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: drug exposure at steady-state with 100 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measuring itch by computerized Visual Analog Scale Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measuring pain by computerized Visual Analog Scale Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AYA EHR visits for PrEP initiation and maintenance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Needle placement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients treated with HFrEF GDMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean interstitial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Statin or other lipid lowering therapy initiation or intensification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Premenstrual Syndrome Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achieving a target LDL-C blood level of 70 mg/dl or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in clinical evaluation of resin based composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of varegacestat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of a temporary magnetic system for tarsorrhaphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physician's diagnostic confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in etiological diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fitbit Active Zone Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Action Planning (BAP) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of adherence to the Otago Exercise Program (OEP)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proptosis Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth Comfort Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Actual falls
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of CPX101
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of CPX101
Endpoint domain: Adverse events/effects
Primary endpoint: Pain level measured by Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anaerobic Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intra-Abdominal Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Liver steatosis by CAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver steatosis on ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA transcription levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cord to canal diameter ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hippocampal subfield volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid plaque height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular global longitudinal strain (LVGLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milligrams of Morphine Equivalent Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Total sleep time (TST)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Fragmentation index (FI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wake after sleep onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in 24h glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with no significant nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation-emergent Signs and Symptoms (DESS) Questionnaire Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Seizures
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants at Suicidality Risk
Endpoint domain: Adverse events/effects
Primary endpoint: GMTs of anti-toxoids IgGs in serum at V4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CKD Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of subjects with hemoglobin level ≥12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of Life Measurement - Jaundice Dimension
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Synovial hypertrophy domain score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: High-load working memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: O-GlcNAcylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Destructive Behavior in Renewal Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Destructive Behavior in Super-Resurgence Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Destructive Behavior in Reinstatement Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total ORAC Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ilaprazole and aceclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of ilaprazole and aceclofenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure control status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lipid control status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight control status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of grade 2 or higher paclitaxel-induced sensory peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Patient and caregiver access to hydroxyurea (HU)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perceived barriers to hydroxyurea (HU) use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healthcare providers' knowledge and attitudes toward providing HU
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Risk of clinical outcomes among familial LPD and family members
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum creatine kinase (CK) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of virtual reality-based vestibular rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of virtual reality-based vestibular rehabilitation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of early onset primary adverse events (PAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from documented atrial tachyarrhythmia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from acute procedural failure
Endpoint domain: Adverse events/effects
Primary endpoint: MRC dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Deformity Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sagittal Spinal Posture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-Specific QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: alveolar ridge dimensional changes in height and width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass Correlation Coefficient (ICC) for ASH Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraclass Correlation Coefficient (ICC) for IASH Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of Variation (CV) for ASH and IASH Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Detectable Change (MDC) for ASH and IASH Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force Ratios Between ASH and IASH Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Suicide-related event (SRE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of spinopelvic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal Bone remodeling around the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in miRNA expression response to acute all-out exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who achieve a complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived Sacredness of Life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Suicide-Related Thoughts and Behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Affect Misattribution Procedure: Implicit affinity to sacredness of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Death/Life Implicit Association Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Depression Anxiety Stress Scale- 21 (DASS 21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency and severity of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: number of subjects with Adverse Events (AEs), adverse device effects (ADEs), serious AEs (SAEs) and serious device effects (SADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free survival rate at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Wound Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with ≥ 50% reduction in pre procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change in height of scar pre and post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of reduction in The Patient and Observer Scar Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of change in Vancouver Scar Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of good to excellent subjective improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cancer related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Color difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in degree of kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Local Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Brief Pain Inventory (BPI) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 1-year cumulative recurrence-free patient percentage
Endpoint domain: Mortality/survival
Primary endpoint: Number of MII oocyte retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Bladder Cancer Need Assessment Survey (BCNAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of diabetes remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic health (Oral glucose tolerance test, OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Viscoelasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Clinically Relevant Postoperative Pancreatic Fistula (POPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Growth pattern in infants and children with heart diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retreatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Time in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrition status - 3-Minute Nutrition Screening (3-minNS) tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVDs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thrombus burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breastfeeding Diagnostic and Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Edinburgh Mental Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nottingham Health Profile (NSP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heart rhythm abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: birth self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: birth health belief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with positive microbiological culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with histological features of periprosthetic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with positive NGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes